Alycia Shoultz

Alycia Shoultz has extensive work experience in the pharmaceutical industry. Alycia is currently working as the Associate Director of Platform Technology at Aliada Therapeutics, where they are responsible for the molecular design, characterization, and validation of constructs utilizing blood brain barrier transcytosis enabling platform technology. Alycia also leads the design, production, and characterization of large molecule conjugates demonstrating BBB transcytosis and drives synergy between Aliada and key CRO and CMDO collaborators.

Before joining Aliada Therapeutics, Alycia worked at Merck as a Senior Scientist from February 2012 to July 2022. Prior to that, they held the positions of Senior Scientist from January 2018 to July 2022 and Scientist from May 2016 to January 2018 at the same company.

Alycia also has experience working at Boehringer Ingelheim as a Research Scientist. During their time there, they designed expression constructs supporting early drug discovery, managed CRO molecular biology and protein production efforts, and provided protein purification support for HTS enablement.

Alycia's earlier experience includes working as a Contract Scientist at Boehringer Ingelheim, where they developed a novel scale-up process for expression of recombinant proteins, and as an Associate Scientist/Project Manager at Protein Sciences Corporation.

Alycia began their career as an Associate Scientist at Pfizer - Contract.

Overall, Alycia has a strong background in molecular design, characterization, protein production, and purification, and has contributed significantly to pharmaceutical research and development throughout their career.

Alycia Shoultz holds a Bachelor of Science (BSc) degree in Biology, General from Messiah College. Alycia further pursued their education at Quinnipiac University, where they obtained a Master of Science (M.S.) degree in Molecular and Cell Biology.